We have located links that may give you full text access.
<Editors' Choice> Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group.
Nagoya Journal of Medical Science 2018 May
Information on patterns of clinical care for elderly breast cancer patients is lacking. The aims of this study are two-fold, firstly, to clarify daily practice treatments for elderly breast cancer patients in Japan, and secondly, to plan a prospective clinical trial to address unresolved clinical questions. We investigated practice care of elderly breast cancer patients in 38 institutions of the Japan Clinical Oncology Group (JCOG). Questionnaires asked: (1) definition of "elderly" for each treatment, (2) clinical standard anti-HER2 therapy in each age-group, (3) recommended docetaxel dose in each age-group, (4) considerations for future clinical trials, and (5) other information about geriatric oncology concerning breast cancer. The upper age-limit for surgery and irradiation therapy was generally 80 years, while many physicians considered anti-cytotoxic adjuvant therapy unsuitable for patients >70-75 years. For HER2-positive metastatic breast cancer, 82% of physicians recommended docetaxel (DTX) plus trastuzumab plus pertuzumab (DTP) as standard care for patients aged 65-70, although 54% of physicians avoided DTP for those aged 71-75 as first-line standard preference. Most physicians recommended 75 mg/m2 DTX for both 65-70 (63%) and 70-75 (52%) age-groups, but not for those over 75. Many physicians (73%) recommended 60 mg/m2 DTX first. Most (97%) agree that the vulnerability of each elderly patient in a clinical trial should be assessed by comprehensive geriatric assessment. This is the first questionnaire study of care patterns for elderly breast cancer patients. Physicians considered different drug regimens and dosages according to patients' fragility.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app